SCHEMBL5563208

SCHEMBL5563208

Cc1ccc(-c2cccc(C(=O)CC(=O)Nc3cc(C(F)(F)F)ccc3NC(=O)OC(C)(C)C)c2)cn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.43
ALDH1A1 P00352 1/20 0.43
KMT2A Q03164 1/20 0.43
CCR2 P41597 2/20 0.42
RXRA P19793 1/20 0.41
NR1H2 P55055 1/20 0.41
NR1H3 Q13133 1/20 0.41
RXFP1 Q9HBX9 1/20 0.40
SLC1A3 P43003 1/20 0.39
SLC1A2 P43004 1/20 0.39
SLC1A1 P43005 1/20 0.39
VNN1 O95497 1/20 0.39
CYP17A1 P05093 2/20 0.37
RIPK1 Q13546 1/20 0.36
IGF1R P08069 1/20 0.36
MAP2K4 P45985 1/20 0.36
GRIN1 Q05586 1/20 0.36
GRIN2B Q13224 1/20 0.36
LCK P06239 2/20 0.36
KDR P35968 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5558230 0.91 MEN1 (0.41) MEN1ALDH1A1KMT2ACCR2RXRA
SCHEMBL5557361 0.91 MAPT (0.42) MEN1ALDH1A1KMT2ACCR2RXRA
SCHEMBL5556638 0.90 MEN1 (0.44) MEN1ALDH1A1KMT2ACCR2RXFP1
SCHEMBL5562711 0.90 KCNQ4 (0.41) CYP17A1
SCHEMBL5561257 0.90 MEN1 (0.41) MEN1ALDH1A1KMT2ACCR2RXRA
SCHEMBL5562331 0.89 MEN1 (0.40) MEN1ALDH1A1KMT2ACCR2RXRA
SCHEMBL27597128 0.89 ALDH1A1 (0.50) MEN1ALDH1A1KMT2ASLC1A3SLC1A2
SCHEMBL5563428 0.89 MEN1 (0.44) MEN1ALDH1A1KMT2ACCR2RXRA
SCHEMBL5556798 0.89 MEN1 (0.40) MEN1ALDH1A1KMT2ACCR2RXRA
SCHEMBL5559202 0.89 CCR2 (0.46) MEN1ALDH1A1KMT2ACCR2RXRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1474416-B1 DIHYDROBENZODIAZEPIN-2-ONE-DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS HOFFMANN LA ROCHE (CH) 2007-09-26 EP disclosed
US-6949542-B2 Dihydro-benzo[b][1,4]diazepin-2-one derivatives HOFFMAN-LA ROCHE INC. (US) 2005-09-27 US disclosed
EP-1474416-A1 DIHYDROBENZODIAZEPIN-2-ONE-DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2004-11-10 EP disclosed
US-20030166639-A1 Dihydro-benzo[b][1,4]diazepin-2-one derivatives F. HOFFMAN-LA ROCHE AG (CH) 2003-09-04 US disclosed
WO-2003066623-A1 DIHYDROBENZODIAZEPIN-2-ONE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2003-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166639-A1 Dihydro-benzo[b][1,4]diazepin-2-one derivatives CYP1B1, GRIN2B, CYP4B1 MEN1 1739/4885ALDH1A1 314/4885KMT2A 1661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.